Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study
Authors:
- Jinghao Nicholas NgiamJNJinghao Nicholas Ngiam
- Enoch Xueheng LoyELEnoch Xueheng Loy
- Matthew Chung Yi KohMKMatthew Chung Yi Koh
- Calvin J. ChiewCCCalvin J. Chiew
- Russell Jingxian LiRLRussell Jingxian Li
- Su Chi LimSLSu Chi Lim
- E Shyong TaiETE Shyong Tai
- Yong Mong BeeYBYong Mong Bee
- Wai Leng ChowWCWai Leng Chow
- David Chien Boon LyeDLDavid Chien Boon Lye
- Yew Woon ChiaYCYew Woon Chia
- Mark Yan Yee ChanMCMark Yan Yee Chan
Open Access
- 3 June 2026
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (7) , 1955-1976
Abstract
Introduction Patients with type 2 diabetes mellitus (T2DM) are at increased risk of post-acute sequelae after COVID-19 (PASC). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and metformin may have systemic benefits beyond glycemic control. We evaluated the impact of prior SGLT2i and metformin use on the risk of post-acute COVID-19 complications. Methods We conducted a retrospective, population-based cohort study using national healthcare claims databases, from July 1, 2021 to February 28, 2023. Cohorts were stratified based on SGLT2i or metformin, against patients had not received these medications. Overlap weighting was applied to adjust for baseline differences in demographics, vaccination status, comorbidities, and prior healthcare utilization. Competing-risks regression models were used to assess differences in the risk of long-COVID outcomes between 31 and 300 days post-infection. Results Among 71,698 patients with T2DM, 22,501 (31.4%) had prior SGLT2i use, and 66,792 (93.1%) had prior metformin use. Compared with non-SGLT2i users, patients treated with SGLT2i had a significantly lower risk of neurological sequelae (aHR = 0.60 [0.45–0.81]), particularly memory and cognitive impairment (aHR = 0.63 [0.41–0.98]). SGLT2i was also associated with a reduced risk of post-acute symptoms (aHR = 0.87 [0.77–0.99]). Metformin use was associated with significantly lower risk of composite post-acute outcomes (aHR = 0.80 [0.68–0.96]) and post-acute symptoms (aHR = 0.77 [0.63–0.93]). Amongst patients on metformin, the addition of SGLT2i further lowered the risk of neurological sequelae (aHR = 0.81 [0.71–0.93]) and composite symptoms (aHR 0.87 [0.76–0.99]). Conclusion SGLT2i and metformin use were associated with a lower risk of PASC and post-acute symptoms. There may be additional protective benefits when both agents are used concurrently.Keywords
This publication has 58 references indexed in Scilit:
- Nirmatrelvir/ritonavir treatment and risk for postacute sequelae of COVID-19 in older SingaporeansClinical Microbiology and Infection, 2024
- Autoimmune Sequelae After Delta or Omicron Variant SARS-CoV-2 Infection in a Highly Vaccinated CohortJAMA Network Open, 2024
- Long-term neuropsychiatric sequelae of Delta versus Omicron SARS-CoV-2 infectionClinical Microbiology and Infection, 2023
- Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmissionClinical Microbiology and Infection, 2023
- Anti‐inflammatory effects of sodium‐glucose cotransporter‐2 inhibitors in COVID‐19IUBMB Life, 2023
- Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19JAMA Network Open, 2022
- Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021JAMA, 2022
- New insights into cellular links between sodium–glucose cotransporter‐2 inhibitors and ketogenesisJournal of Cellular Biochemistry, 2022
- Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney diseaseJournal of Cellular Physiology, 2021
- Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseasesInternational Journal of Clinical Pharmacy, 2021